

Highlights of This Issue 391

SPECIAL FEATURES

CCR Translations

- 393 | **Response to Combined Molecular Targeting: Defining the Role of P-STAT3**
Ann Marie Egloff and Jennifer R. Grandis
See article p. 483

CCR New Strategies

- 396 | **New Strategies in Acute Lymphoblastic Leukemia: Translating Advances in Genomics into Clinical Practice**
Charles G. Mullighan

Molecular Pathways

- 401 | **Tumor Suppressor *CHK2*: Regulator of DNA Damage Response and Mediator of Chromosomal Stability**
Ailine Stolz, Norman Ertych, and Holger Bastians

Review

- 406 | **Drug Transporters and Imatinib Treatment: Implications for Clinical Practice**
Karel Eechoute, Alex Sparreboom, Herman Burger, Ryan M. Franke, Gaia Schiavon, Jaap Verweij, Walter J. Loos, Erik A.C. Wiemer, and Ron H.J. Mathijssen

HUMAN CANCER BIOLOGY

- 416 | **Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and MDM2 Amplification in Sarcomagenesis**
Moriko Ito, Louise Barys, Terence O'Reilly, Sophie Young, Bella Gorbacheva, John Monahan, Sabine Zumstein-Mecker, Peter F. Choong, Ian Dickinson, Philip Crowe, Christine Hemmings, Jayesh Desai, David M. Thomas, and Joanna Lisztwan
- 427 | **Expression and Functional Significance of HtrA1 Loss in Endometrial Cancer**
Sally A. Mullany, Mehdi Moslemi-Kebria, Ramandeep Rattan, Ashwani Khurana, Amy Clayton, Takayo Ota, Andrea Mariani, Karl C. Podratz, Jeremy Chien, and Viji Shridhar
- 437 | **Endogenous Versus Tumor-Specific Host Response to Breast Carcinoma: A Study of Stromal Response in Synchronous Breast Primaries and Biopsy Site Changes**
Julie M. Wu, Andrew H. Beck, Lisa L. Pate, Daniela Witten, Shirley X. Zhu, Kelli D. Montgomery, Kimberly H. Allison, Matt van de Rijn, and Robert B. West

CANCER THERAPY: PRECLINICAL

- 447 | **Vandetanib Improves Anti-Tumor Effects of L19mTNF α in Xenograft Models of Esophageal Cancer**
Marika Crescenzi, Luca Persano, Giovanni Esposito, Elisabetta Zulato, Laura Borsi, Enrica Balza, Alberto Ruol, Ermanno Ancona, Stefano Indraccolo, and Alberto Amadori
- 459 | **Targeting the Urokinase Plasminogen Activator Receptor Inhibits Ovarian Cancer Metastasis**
Hilary A. Kenny, Payton Leonhardt, Andras Ladanyi, S. Diane Yamada, Anthony Montag, Hae Kyung Im, Sujatha Jagadeeswaran, David E. Shaw, Andrew P. Mazar, and Ernst Lengyel

- 472 **HGF Rescues Colorectal Cancer Cells from EGFR Inhibition via MET Activation**
David Liska, Chin-Tung Chen, Thomas Bachleitner-Hofmann, James G. Christensen, and Martin R. Weiser
- 483 **Combined Blockade of Src Kinase and Epidermal Growth Factor Receptor with Gemcitabine Overcomes STAT3-Mediated Resistance of Inhibition of Pancreatic Tumor Growth**
Nagathihalli S. Nagaraj, M. Kay Washington, and Nipun B. Merchant
See commentary p. 393
- 494 **Nutlin-3a Is a Potential Therapeutic for Ewing Sarcoma**
Kathleen I. Pishas, Fares Al-Ejeh, Irene Zinonos, Raman Kumar, Andreas Evdokiou, Michael P. Brown, David F. Callen, and Paul M. Neilsen
- 505 **Notch Pathway Inhibition Significantly Reduces Rhabdomyosarcoma Invasiveness and Mobility *In Vitro***
Josep Roma, Anna Masià, Jaume Reventós, Josep Sánchez de Toledo, and Soledad Gallego
- 514 **Distinct Interactions Between c-Src and c-Met in Mediating Resistance to c-Src Inhibition in Head and Neck Cancer**
Banibrata Sen, Shaohua Peng, Babita Saigal, Michelle D. Williams, and Faye M. Johnson
- 525 **Forkhead Transcription Factor FOXO1 is a Direct Target of Progestin to Inhibit Endometrial Epithelial Cell Growth**
Satoru Kyo, Junko Sakaguchi, Tohru Kiyono, Yutaka Shimizu, Yoshiko Maida, Yasunari Mizumoto, Noriko Mori, Mitsuhiro Nakamura, Masahiro Takakura, Kiyohiko Miyake, Masaru Sakamoto, and Masaki Inoue
- 538 **Conditionally Replicating Adenovirus Expressing TIMP2 for Ovarian Cancer Therapy**
Sherry W. Yang, James J. Cody, Angel A. Rivera, Reinhard Waehler, Minghui Wang, Kristopher J. Kimball, Ronald A. Alvarez, Gene P. Siegal, Joanne T. Douglas, and Selvarangan Ponnazhagan

IMAGING, DIAGNOSIS, PROGNOSIS

- 550 **Longitudinal Investigation of Permeability and Distribution of Macromolecules in Mouse Malignant Transformation using PET**
Cecilie B. Rygh, Shengping Qin, Jai W. Seo, Lisa M. Mahakian, Hua Zhang, Roger Adamson, Jane Q. Chen, Alexander D. Borowsky, Robert D. Cardiff, Rolf K. Reed, Fitz-Roy E. Curry, and Katherine W. Ferrara

CANCER THERAPY: CLINICAL

- 560 **Cancer Therapy Associated Bone Loss: Implications for Hip Fractures in Mid-Life Women with Breast Cancer**
Beatrice J. Edwards, Dennis W. Raisch, Veena Shankaran, June M. McKoy, William Gradishar, Andrew D. Bunta, Athena T. Samaras, Simone N. Boyle, Charles L. Bennett, Dennis P. West, and Theresa A. Guise
- 569 **A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer**
Ronan J. Kelly, Deborah Draper, Clara C. Chen, Robert W. Robey, William D. Figg, Richard L. Piekarz, Xiaohong Chen, Erin R. Gardner, Frank M. Balis, Aradhana M. Venkatesan, Seth M. Steinberg, Tito Fojo, and Susan E. Bates
- 581 **A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer**
Martijn P. Lolkema, Hendrik-Tobias Arkenau, Kevin Harrington, Patricia Roxburgh, Rosemary Morrison, Victoria Roulstone, Katie Twigger, Matt Coffey, Karl Mettinger, George Gill, T.R. Jeffrey Evans, and Johann S. de Bono
- 589 **Phase 1 Study of Valproic Acid in Pediatric Patients with Refractory Solid or CNS Tumors: A Children's Oncology Group Report**
Jack M. Su, Xiao-Nan Li, Patrick Thompson, Ching-Nan Ou, Ashish M. Ingle, Heidi Russell, Ching C. Lau, Peter C. Adamson, and Susan M. Blaney

598 | **Modulation of Genetic and Epigenetic Biomarkers of Colorectal Cancer in Humans by Black Raspberries: A Phase I Pilot Study**

Li-Shu Wang, Mark Arnold, Yi-Wen Huang, Christine Sardo, Claire Seguin, Edward Martin, Tim H.-M. Huang, Ken Riedl, Steven Schwartz, Wendy Frankel, Dennis Pearl, Yiqing Xu, John Winston III, Guang-Yu Yang, and Gary Stoner

611 | **Pharmacokinetically Guided Phase 1 Trial of the IGF-1 Receptor Antagonist RG1507 in Children with Recurrent or Refractory Solid Tumors**

Rochelle Bagatell, Cynthia E. Herzog, Tanya M. Trippett, Joseph F. Grippo, Georgina Cirrincione-Dall, Elizabeth Fox, Margaret Macy, Jennifer Bish, Patricia Whitcomb, Alberta Aiken, Gerry Wright, Sergey Yurasov, Frank M. Balis, and Lia Gore

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

620 | **Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib**

Astrid A.M. van der Veldt, Karel Eechoute, Hans Gelderblom, Jourik Gietema, Henk-Jan Guchelaar, Nielka P. van Erp, Alfons J.M. van den Eertwegh, John B. Haanen, Ron H.J. Mathijssen, and Judith A.M. Wessels


CORRECTIONS

630 | **Correction: Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors**

631 | **Correction: *In vitro* and Clinical Studies of Gene Therapy with Recombinant Human Adenovirus-*p53* Injection for Oral Leukoplakia**

ABOUT THE COVER

Rapid restoration of tumor microvasculature and perfusion in esophageal cancer xenografts treated with a vascular disrupting agent. Kyse-30 tumors were analyzed two weeks after administration of one single dose of the immunoconjugate L19mTNFa. Microvessels were stained by anti-CD31 (red), whereas perfusion was evaluated by injection of Dextran-FITC 70 kDa (green). Nuclei were stained by TOPRO-3 (blue). For further details, please see Crescenzi and coworkers on page 447 in this issue.



Clinical Cancer Research

17 (3)

Clin Cancer Res 2011;17:391-631.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/17/3>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/17/3>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.